Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol

News

New Approaches to Treatment

The Biggest Changes in 20 Years Are Coming

May/June 2015

 1  |  2  |  Next > 

New Approaches to Treatment

The decade of the 2020s will see the biggest change in HIV treatment paradigms since the birth of HAART two decades ago. Newer regimens will emphasize tolerability and adherence, without sacrificing potency, and long-acting injectables will debut. Yet while we contemplate the exciting new drugs that may emerge, there must be equal emphasis on how we deliver care. Even the most stunning advances in treatment will disappoint if we do not solve the harder challenges around care linkage, continuous care engagement, and uninterrupted access to ART for both prevention and therapy.


Antiretroviral Therapy

Since March 1987, FDA has approved over 40 drugs for the treatment of HIV, including a few extended release formulations. Yet our armamentarium is less robust than the numbers suggest, as three are no longer marketed, and 11 are no longer recommended by guidelines from the Department of Health and Human Services (DHHS). Others have simply stepped aside as alternatives to more potent, forgiving, and tolerable therapies. As cross-resistance rapidly eliminates entire classes and limits treatment options, we still find ourselves at the end of the line all too quickly. Today's pipeline however is robust, and licensure for its drugs will take us well into the Roaring '20s.

An entire group of drugs likely to win FDA approval* over the next two to three years is the tenofovir alafenamide (TAF) family of fixed-dose compounds:

  • elvitegravir/cobicistat/FTC/TAF (expected November 2015),
  • FTC/TAF (expected 2016),
  • rilpivirine/FTC/TAF (expected 2017), and
  • darunavir/cobicistat/FTC/TAF (2016-17).
Advertisement

These will cannibalize Stribild, Truvada, Complera, and Atripla, and provide the first single-tablet regimen (STR) containing a boosted protease inhibitor (PI). The tenofovir prodrug TAF concentrates in cells rather than plasma, causing less renal and bone toxicity compared to tenofovir DF (TDF; Viread), and may have an advantage in potency and resistance. The decrease in total and LDL cholesterol associated with TDF (Randell, 2010), however, appears to be lost with TAF.

Following TAF, NRTIs will be expected to have high potency, exceptionally low toxicity, daily or less frequent dosing potential, and high resistance barriers in order to play. Only time will tell whether EFdA, one of the few current NRTI candidates, will live up to its promise of potency and resistance advantage in the hands of Merck. If so, FDA approval might occur in the mid-20s.

The current NNRTI pipeline is thin, but Merck's doravirine (MK-1439) is in Phase 3, having exhibited potency and low central nervous system (CNS) toxicity (Gatell, 2014) and could reach pharmacy shelves in 2017-18. On a similar course is fixed-dose doravirine/TDF/3TC, a compound that could potentially take advantage of generic 3TC (available now) and generic TDF (expected 2018).

Protease inhibitor development has slowed as companies have focused instead on incorporating cobicistat into FDCs, or fixed-dose combinations (EvoTaz, Prezcobix). TaiMed, though, is chasing the holy grail of a potent unboosted PI with TMB-607 (formerly from Ambrilla). This nanoformulation is active in the lab against PI resistance mutations and aims for monthly or quarterly dosing. This is the kind of innovation that will be required of future PIs. We may indeed see the boosted PIs find a new niche as tertiary therapy in the '20s.

Integrase inhibitors (INIs) have stolen the spotlight lately, largely due to the high potency and tolerability and favorable resistance profile of dolutegravir, the first INI for daily dosing without a booster. Reformulated once-daily raltegravir is in trials and, if successful, headed toward possible approval in 2016. Of newer INIs in development, the most advanced is once-daily GS-9883, which also doesn't require boosting. Now in Phase 2, successful trials could lead toward FDA approval by the end of the decade.

Earlier in development are the LEDGINs whose mechanism of action differs from the currently licensed strand transfer inhibitors, opening the possibility of combination INI strategies in the mid '20s.


Long-Acting Meds

The promise of long-acting nanoformulation injectables for both treatment and prevention is the most riveting story to emerge in decades. Dolutegravir's longer acting cousin, cabotegravir (GSK12657744, or 744, CAB), and long-acting rilpivirine are being studied together as monthly maintenance injections for treatment (and cabotegravir as a quarterly injection for PrEP). Meanwhile, an oral dolutegravir/rilpivirine co-formulation is planned for use as two-drug maintenance (as a switch for those who have achieved viral suppression on an initial three-drug regimen and have no history of viral resistance), based on LATTE results (Margolis, 2015). Oral cabotegravir will be developed as well, but used only as part of an initial regimen in persons who are transitioning to maintenance with injectable CAB/RPV.

If the nanos are safe and effective for maintenance, FDA approval could come by the turn of the decade. But success is not a slam-dunk. There are potential pitfalls to long-acting injectables such as the risk of incremental toxicity that cannot be halted by stopping drug, and resistance due to a long "pharmacologic tail" that could expose the virus to lengthy intervals of suboptimal dosing if repeated injections are not delivered on time. Barriers to safety monitoring and drug delivery must be identified and addressed, including exploration of new distribution systems such as designated pharmacy partners and home health options. Clearly, the 744/rilpivirine adventure is being closely watched by biopharmas itching to embrace nanotechnology and explore the acceptability of non-oral therapies.

Fusion inhibitors could get new life if albuvirtide, a better-looking cousin of enfuvirtide (T-20), can capitalize on its 11-day half-life, potentially allowing weekly dosing by injection. PRO-140, a monoclonal CCR5 antagonist (administered weekly or biweekly), and the monthly anti-CD4 monoclonal antibody TMB-360 (second generation ibalizumab) are moving (slowly) in clinical trials. The anti-HIV neutralizing antibody 3BNC117 showed promise in an early human trial. This new direction toward injectables could make the '20s very interesting indeed.

Bristol-Myers Squibb (BMS) is attacking two new targets that could also change the treatment paradigm. An attachment inhibitor (AI), fostemsavir (BMS-663068), is in Phase 3, but only for highly treatment-experienced patients, as twice-daily dosing complicates use in initial therapy. Meanwhile, BMS-955176, a maturation inhibitor (MI), disrupts a late stage in viral replication and is entering Phase 2 for both treatment-naïve and experienced patients. If successful, FDA approval for the AI could come in late 2017 to early 2018, and for the MI in 2020-21. Other AIs and MIs will surely emerge in the late teens and early '20s and could provide options for treatment of multidrug-resistant virus as well as displace the NRTI class as first-line therapy.

Gene therapies, including the Sangamo zinc-finger nuclease approach, continue to make slow progress (Wang, 2015). While therapeutic vaccines have missed the sweet spot to date, newer vector-based gene immunotherapy raises hope of spanning the treatment and prevention realms (Gardner, 2010).

Finally, chronic inflammation contributes to excess non-AIDS morbidity and mortality in spite of viral suppression. Two potential approaches to controlling inflammation are in clinical trials, and this line of research is sure to expand in the next decade. Cenicriviroc blocks CCR2 and affects surrogate markers of inflammation, in addition to its CCR5-mediated antiviral effect. It is now under study for fatty liver (non-alcoholic hepatic steatosis; NASH). The NIH REPRIEVE trial will look at the impact of pitavastatin on cardiac outcomes over five years, with results in the '20s (reprievetrial.org).

 1  |  2  |  Next > 

More From This Resource Center


10 Questions to Ask Yourself Before You Begin HIV Treatment

Are Your HIV Meds Working? Warning Signs and False Alarms


Related Stories

More on HIV Medications
HIV Drugs in Development


This article was provided by Test Positive Aware Network. It is a part of the publication Positively Aware. Visit TPAN's website to find out more about their activities, publications and services.
 

 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our advertising policy.